Ivoclar Vivadent, Inc.
$405.7K 1,041 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BlueRock Therapeutics LP
BlueRock Therapeutics LP reported $405,904.40 across General Payments, Research, and Ownership to 4 physicians and teaching hospitals across 4 transactions.
- $405.9K Above-median payer
- All-tracks total
- 4 Below-median volume
- Transactions
- 4 Below-median reach
- Recipients
- +$281.2K
- General Payments vs PY2023
BlueRock Therapeutics LP reported $405,904.40 across all CMS Open Payments tracks (General + Research + Ownership) to 4 physicians and teaching hospitals in Program Year 2024 - ranking #815 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $405,904.40, averaging $101.5K per recipient.
BlueRock Therapeutics LP's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
14/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer bluerock-therapeutics-lp BlueRock Therapeutics LP
$405.9K · #815/1,925 · 0.0% industry · PY2024
- TOT $405.9K
- RANK #815
- SHARE 0.0%
- TXN 4
- RCP 4
- CAT 1
- GEN $405.9K
- ΔGEN +$281.2K
- TOP1 72.7%
- PY 2024
Volume peers
Nearest volume peer: Ivoclar Vivadent, Inc. ($405.7K)
BlueRock Therapeutics LP sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
BlueRock Therapeutics LP's CMS-reported General Payments increased by $281.2K (+225.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: BLUEROCK THERAPEUTICS LPPY2024: BlueRock Therapeutics LP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $124,742.63
- PY2024
- $405,904.40
What the Data Shows for BlueRock Therapeutics LP
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For BlueRock Therapeutics LP that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 1 general-payment categories charted below, "Acquisitions" is the largest at $405.9K across 4 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, BlueRock Therapeutics LP's largest category was "Acquisitions" at $405.9K - 100.0% of General Payments.
How BlueRock Therapeutics LP divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $405.9K | 4 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $405,904.40 (100.0%) of $405,904.40 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BlueRock Therapeutics LP
The five named recipients with the highest reported General Payments from this company
- 1
Bruce R Blazar
$295,048.16 across 1 reported transactions
- 2
Viviane S Tabar
$57,460.08 across 1 reported transactions
- 3
Brendon P Boot
$40,262.31 across 1 reported transactions
- 4
Kwan-Hong Min
$13,133.85 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
BlueRock Therapeutics LP ranks #815 of 1,925 by total payments (top 42% by spend) but is notably more concentrated than that alone would suggest -- #294 of 1,838 by HHI (top 16% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Zerigo Health, Inc. : $7.5K total payments, HHI 5622
- Medivation Services LLC : $192.46 total payments, HHI 5620
- Inpeco North America, Inc : $7.5K total payments, HHI 5612
- FFF Enterprises, Inc. : $3.6K total payments, HHI 5610
- Retropsoas Technologies, LLC : $14.6K total payments, HHI 5606
- Ipsen Biopharm Limited : $13.1K total payments, HHI 5603
- BlueRock Therapeutics LP (this company) : $405.9K total payments, HHI 5593
- Nidek Co., Ltd. : $29.8K total payments, HHI 5592
- DiaSorin Inc. : $371.5K total payments, HHI 5574
- Bavarian Nordic A/S : $68.0K total payments, HHI 5563
- Mindera Corp : $7.5K total payments, HHI 5556
- Ferring International Pharmascience Center US : $282.61 total payments, HHI 5546
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BlueRock Therapeutics LP's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BlueRock Therapeutics LP.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BlueRock Therapeutics LP.
Showing 6 of 1,924 companies with CMS-reported payment data.
Amarin Pharma Inc.
$405.1K 300 recipients
Compare payment profiles
Nova Eye, Inc.
$404.7K 474 recipients
Compare payment profiles
Mizuho America, Inc.
$403.0K 57 recipients
Compare payment profiles
Onkos Surgical, Inc.
$402.3K 461 recipients
Compare payment profiles
Geistlich Pharma, North America, Inc.
$401.7K 2,543 recipients
Compare payment profiles
Put this to use
BlueRock Therapeutics LP ranks #815 of 1,925 by all-tracks total payments, led by "Acquisitions".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Acquisitions" spend across every manufacturer, not just BlueRock Therapeutics LP. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.